VC005

Phase 3Small molecule

JJiangsu vcare pharmaceutical technology co., LTD

VC005 is one of 131 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Atopic DermatitisRecruiting

VitiligoActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Atopic DermatitisPhase 3

Recruiting

VitiligoPhase 2

Active, not recruiting

Ankylosing SpondylitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

1 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Cimzia

UCB

Preclinical

30 5

Simponi

Johnson & Johnson

Preclinical

19 6

Enbrel

IImmunex

Preclinical

64 7

Arcoxia

Novartis

Preclinical

4 8

Ilaris

Novartis

Preclinical

3 9

Actos

Takeda

Preclinical

2 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Vitiligo

NCT07172347

Phase 3Recruiting

Ankylosing Spondylitis

NCT07172360

Phase 3Recruiting

Atopic Dermatitis

NCT06723080

Q2 2028

Phase 3Recruiting

Atopic Dermatitis

NCT07592585

Clinical

Trials by Indication[1]

Atopic Dermatitis6 trials

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 2·NCT05997927·149 enrolled

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 3·NCT06723080·480 enrolled

Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 2·NCT06891040·114 enrolled

Show 3 more trials

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT07329101·10 enrolled

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT06009094·80 enrolled

Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 3·NCT07592585·360 enrolled

Ankylosing Spondylitis2 trials

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 2·NCT05814939·180 enrolled

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 3·NCT07172360·420 enrolled

Vitiligo1 trial

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 2·NCT07172347·120 enrolled

Rheumatoid Arthritis1 trial

A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT05874622·30 enrolled

Adult1 trial

The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT06974292·6 enrolled

2 more indications

Tics1 trial

Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT05138770·78 enrolled

Unspecified1 trial

Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT05354752·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for VC005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VC005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VC005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu vcare pharmaceutical technology co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu vcare pharmaceutical technology co., LTD

VC005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Trials by Indication[1]

Atopic Dermatitis6 trials

Ankylosing Spondylitis2 trials

Vitiligo1 trial

Rheumatoid Arthritis1 trial

Adult1 trial

Tics1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News